Last updated: August 1, 2026
Dichlorphenamide is an orally administered carbonic anhydrase inhibitor marketed in the U.S. as Keveyis for primary periodic paralysis. The product is a 50 mg immediate-release tablet with a relatively simple excipient system. The strongest commercial opportunities are generic 50 mg supply, lower-dose titration products, pediatric or swallowing-friendly dosage forms, and manufacturing improvements that reduce tablet variability and packaging cost.
What is the FDA-approved formulation of dichlorphenamide?
Keveyis is supplied as a 50 mg immediate-release tablet. The FDA-approved inactive ingredients are:
| Excipient |
Likely formulation function |
| Lactose monohydrate |
Diluent and compressibility aid |
| Microcrystalline cellulose |
Diluent, dry-binder, disintegration support |
| Croscarmellose sodium |
Superdisintegrant |
| Povidone |
Binder |
| Magnesium stearate |
Lubricant |
| Colloidal silicon dioxide |
Glidant and moisture-flow aid |
| Sodium lauryl sulfate |
Wetting agent and dissolution aid |
The formulation is designed for immediate release rather than modified release. The approved product is a scored tablet, which supports dose adjustment but does not eliminate the commercial value of a dedicated lower-strength presentation. The reference product label identifies the active ingredient as dichlorphenamide and lists a 50 mg tablet strength for oral administration. [1]
Dichlorphenamide has low daily dose requirements relative to many chronic medicines, but dose titration and tolerability make tablet handling important. The FDA label recommends starting treatment at 50 mg once daily and increasing the dose according to clinical response and adverse reactions, with a maximum daily dose of 200 mg. [1]
Which excipients are most important for a dichlorphenamide generic?
The highest-priority excipient variables are lactose grade, microcrystalline cellulose grade, sodium lauryl sulfate level, lubricant concentration, and tablet disintegration performance.
Lactose and microcrystalline cellulose
The lactose-cellulose combination provides a conventional platform for direct compression or dry granulation. It can support:
- Adequate tablet hardness at a low active load
- Rapid disintegration
- Acceptable weight uniformity
- Economical high-speed compression
- A familiar excipient profile for regulatory review
Dichlorphenamide tablets contain a relatively small quantity of active pharmaceutical ingredient compared with total tablet mass. Uniform distribution is therefore a central development issue. A direct-compression process may be commercially attractive, but the developer must control segregation between the active ingredient and the excipient blend.
A co-processed lactose-cellulose system could improve flow and content uniformity, although replacing the reference excipient architecture would require comparative dissolution and bioequivalence support. Dry granulation is an alternative where powder flow or segregation is difficult.
Croscarmellose sodium
Croscarmellose sodium is the principal disintegration-control excipient in the labeled product. Its level and intra-granular versus extra-granular placement can affect:
- Disintegration time
- Early dissolution
- Tablet tensile strength
- Sensitivity to compression force
- Performance after storage under elevated humidity
A generic developer should avoid optimizing solely for hardness. Excessive compaction or over-lubrication can delay disintegration and create dissolution differences despite a conventional immediate-release design.
Povidone
Povidone provides binding capacity if granulation is used. Higher molecular-weight grades can improve granule strength but may slow wetting or dissolution if used at excessive levels. A direct-compression formulation may reduce or eliminate povidone, but the resulting blend must maintain content uniformity and mechanical strength.
Sodium lauryl sulfate
Sodium lauryl sulfate is commercially important because it improves wetting of hydrophobic or poorly wetting drug particles. Its concentration should be controlled tightly. Excessive surfactant can alter dissolution profiles, affect tablet mechanical properties, and complicate taste or gastrointestinal tolerability in alternative dosage forms.
A developer should evaluate sodium lauryl sulfate against alternatives such as sodium stearyl fumarate, poloxamers, or other wetting aids only through comparative dissolution, impurity, and stability testing. Substitution may reduce sensitivity to surfactant-related tolerability concerns but can also create a more difficult bioequivalence package.
What formulation opportunities exist beyond the 50 mg Keveyis tablet?
The most practical product opportunities are a 25 mg tablet, a liquid or dispersible formulation, and packaging optimized for chronic low-volume distribution.
25 mg dichlorphenamide tablet
A 25 mg tablet could improve titration and reduce the need to split 50 mg tablets. The opportunity is clinically relevant because dichlorphenamide therapy is titrated based on response and adverse effects, including fatigue, paresthesia, cognitive effects, hypokalemia, and metabolic acidosis. [1]
A 25 mg product would require:
- Dose proportionality or clinical justification
- Comparative dissolution against the 50 mg product
- Demonstration of content uniformity at the lower active load
- A revised tablet design and packaging configuration
- Assessment of tablet identification and medication-error risk
The product could be positioned for initial titration, patients requiring intermediate doses, and patients who cannot reliably split tablets.
Oral liquid or dispersible dosage form
A liquid or dispersible product could target:
- Pediatric patients
- Patients with dysphagia
- Patients with neuromuscular disability
- Caregivers who require flexible dosing
- Specialist centers treating rare disease populations
The principal formulation risks are chemical stability, suspension uniformity, microbial control, adsorption to containers, and dose measurement. Dichlorphenamide has a sulfonamide structure and should be assessed for pH-dependent solubility and precipitation. A true solution would be preferable to a suspension if achievable at a practical concentration, but the required pH and excipient system must remain suitable for chronic use.
Potential excipient classes include purified water, buffers, viscosity modifiers, sweeteners, preservatives, and wetting agents. A preservative-free unit-dose presentation could reduce preservative exposure but would increase packaging and manufacturing cost.
Orally disintegrating or rapidly dispersible tablet
An orally disintegrating tablet could provide a lower-water administration option. Its commercial value is narrower than a 25 mg tablet because the patient population is small and the product would require careful taste evaluation.
The main excipient requirements would include:
- Strong wicking and rapid disintegration
- Low friability
- Controlled mouthfeel
- Minimal active or excipient bitterness
- Packaging protection against moisture
Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavor systems could be considered, but the labeled lactose-containing architecture would not necessarily be retained. Any new dosage form would need a clear clinical and commercial rationale because the reference product is already an oral tablet.
How should a generic developer design the excipient platform?
A two-track development strategy is commercially efficient.
Track 1: Reference-like 50 mg tablet
The first product should closely replicate the established immediate-release profile. The development target is a low-risk abbreviated new drug application with:
- The same 50 mg strength
- A conventional immediate-release tablet
- Similar excipient functions
- Rapid and comparable dissolution
- Low tablet-to-tablet weight variability
- Robust stability under ICH conditions
- Packaging that protects against moisture and physical damage
The formulation should prioritize manufacturing reproducibility over novelty. A simple lactose-microcrystalline cellulose platform with croscarmellose sodium, povidone, colloidal silicon dioxide, and magnesium stearate is a logical starting point. Sodium lauryl sulfate can be retained if it is needed to match dissolution, although its level should be minimized consistent with performance.
Track 2: Differentiated dosage form
A second formulation can pursue commercial differentiation after the reference-like product is established. The most defensible sequence is:
- 50 mg generic tablet
- 25 mg titration tablet
- Dispersible or liquid dosage form
- Pediatric or specialty-care packaging
- Regional products for markets where rare-disease access is constrained
This sequencing limits technical risk while preserving an opportunity for lifecycle management.
What manufacturing and excipient risks affect commercial launch?
Dichlorphenamide is a low-dose, high-value specialty medicine. Manufacturing economics depend more on batch reliability, analytical control, and supply-chain discipline than on raw-material cost.
Content uniformity and segregation
Low-dose active loading creates a risk that dichlorphenamide will segregate from the excipient blend during transfer, hopper storage, or tablet compression. Controls should include:
- Particle-size engineering
- Narrow excipient particle-size distributions
- Controlled blending time
- Low-drop-height transfer
- In-process blend sampling
- Continuous tablet-weight and assay monitoring
Granulation may reduce segregation but adds processing steps, moisture exposure, and scale-up variables.
Lubrication sensitivity
Magnesium stearate can reduce tablet tensile strength and delay dissolution if blending is excessive. Lubrication time should be treated as a critical process parameter. Sodium stearyl fumarate may be evaluated as an alternative where dissolution sensitivity or over-lubrication is problematic.
Moisture and stability
The excipient system should be assessed for moisture uptake, especially if croscarmellose sodium, lactose, or a rapidly disintegrating platform is used. Packaging options include:
- High-barrier HDPE bottles with desiccant
- Aluminum-aluminum blisters
- Cold-form foil for higher moisture protection
- Unit-dose packaging for specialty distribution
Bottle packaging is usually lower cost. Blister packaging may provide better dose accountability and protection but can increase packaging cost for a small-volume product.
Lactose compatibility
Lactose is a conventional and economical diluent, but compatibility testing should assess:
- Drug-excipient degradation
- Reducing-sugar reactions
- Water activity
- Storage at elevated temperature and humidity
- Potential changes in assay or impurities
A lactose-free platform using mannitol, dicalcium phosphate, or additional microcrystalline cellulose could address excipient restrictions, but it would require fresh optimization and may affect tablet size.
What patent and regulatory issues affect dichlorphenamide excipient opportunities?
Dichlorphenamide received FDA approval in 2015 as Keveyis for primary periodic paralysis. The product benefited from orphan-drug exclusivity, which generally runs for seven years from approval under the Orphan Drug Act. The U.S. orphan exclusivity period therefore principally affected market entry through 2022, subject to the statutory framework and product-specific regulatory status. [2]
Orange Book status
The reference product is associated with NDA 208634. FDA Orange Book review is required for current patent listings, pediatric exclusivity, and any listed method-of-use or formulation patents. Orange Book-listed patents can affect an ANDA applicant's certification strategy, including Paragraph IV certification and potential 30-month litigation stays under the Hatch-Waxman Act. [3]
Excipient changes do not automatically avoid patent risk. A patent may claim:
- A method of treating periodic paralysis
- A dosage regimen
- A tablet composition
- A particle-size or manufacturing parameter
- A combination with another therapy
- A formulation or administration method
A generic developer should separate three questions:
| Issue |
Commercial relevance |
| FDA approval exclusivity |
Determines when FDA can approve an ANDA |
| Orange Book patent listing |
Determines certification and litigation exposure |
| Non-listed patent rights |
May create launch or freedom-to-operate risk even if absent from the Orange Book |
Paragraph IV challenges and litigation
A Paragraph IV challenge may be used when an applicant believes a listed patent is invalid, unenforceable, or not infringed. The first applicant to submit a qualifying Paragraph IV certification may receive 180-day generic exclusivity under the applicable statutory conditions. [3]
The practical litigation risk for dichlorphenamide depends on the current Orange Book listing, patent expiration dates, any pediatric extension, and the claims asserted in litigation. A formulation designed around different excipients may reduce literal infringement risk but does not necessarily avoid method-of-use or dosage-regimen claims.
Orphan-drug and biosimilar risk
Biosimilar risk is not relevant to dichlorphenamide because it is a small-molecule drug, not a biologic. The competitive threat is from ANDA-approved generics, authorized-generic arrangements, compounding activity where lawful, and alternative carbonic anhydrase inhibitors.
Orphan designation does not permanently block generic competition. Once applicable exclusivity and patent barriers lapse, generic entry can occur if the applicant satisfies FDA requirements.
How does dichlorphenamide compare with competing carbonic anhydrase inhibitors?
| Product |
Active ingredient |
Primary commercial position |
Formulation opportunity |
| Keveyis |
Dichlorphenamide |
Primary periodic paralysis |
25 mg tablet, liquid, dispersible product |
| Diamox and generics |
Acetazolamide |
Broad neurologic, ophthalmic, diuretic, and altitude indications |
Lower-cost generic competition; broader dosage-form experience |
| Neptazane and generics |
Methazolamide |
Primarily ophthalmic carbonic anhydrase inhibition |
Limited direct substitution for periodic paralysis |
| Topiramate |
Topiramate |
Neurology and migraine |
Competes indirectly in selected neurologic settings |
Dichlorphenamide has a narrower labeled indication than acetazolamide but is differentiated by its orphan-disease positioning and specialist prescribing base. Acetazolamide is a major competitive reference for clinicians and payers because of its lower cost and broad generic availability. A dichlorphenamide commercial strategy therefore depends on disease-specific evidence, specialist access, and reimbursement rather than excipient novelty alone.
What commercial opportunities exist for excipient suppliers and manufacturers?
Excipient suppliers can pursue four opportunities.
Low-dose content-uniformity platform
A co-processed diluent with strong flow and segregation resistance could support dichlorphenamide and other low-dose specialty tablets. The value proposition is reduced blend variability and fewer rejected batches.
Direct-compression platform
A ready-to-use lactose-cellulose system could reduce granulation requirements, shorten manufacturing cycles, and lower capital needs for small specialty batches.
Pediatric liquid platform
A preservative-controlled, low-volume oral liquid platform could support a differentiated dichlorphenamide product. The opportunity depends on pediatric demand, stability, and regulatory acceptance.
Specialty packaging and dose management
Unit-dose blisters, calendar packs, and titration kits could improve adherence and reduce dosing errors. A titration package containing 25 mg and 50 mg units could be commercially useful, although packaging claims and labeling would require FDA review.
What generic launch scenarios exist for dichlorphenamide?
| Launch scenario |
Product |
Commercial effect |
| Single generic entry |
50 mg immediate-release tablet |
Moderate price erosion, limited initial supply |
| Multiple ANDA entrants |
50 mg tablet |
Greater payer pressure and rapid price decline |
| Authorized generic |
Reference-equivalent 50 mg tablet |
Earlier price competition and channel control |
| Differentiated generic |
25 mg or dispersible product |
Higher retention in titration and specialty segments |
| Specialty manufacturer entry |
Small-volume branded or generic supply |
Potentially stable pricing if distribution remains concentrated |
The market is likely to remain concentrated relative to mass-market tablets because primary periodic paralysis is a rare disease. The key commercial variables are patient count, annual treatment cost, payer restrictions, specialty-pharmacy distribution, and the number of approved suppliers.
Key Takeaways
- Keveyis is a 50 mg immediate-release dichlorphenamide tablet containing a conventional lactose-cellulose excipient system.
- A reference-like 50 mg generic is the lowest-risk commercial opportunity.
- A 25 mg tablet has the clearest lifecycle-management rationale because treatment is titrated.
- Liquid, dispersible, and orally disintegrating products could address dysphagia and pediatric use but carry greater development and stability risk.
- Low-dose content uniformity, blend segregation, lubrication, and moisture protection are the main manufacturing issues.
- Dichlorphenamide is a small molecule, so biosimilar competition does not apply.
- Orphan exclusivity principally affected U.S. competition through 2022; current patent and Orange Book review remains necessary for launch planning.
- Excipient innovation is more likely to create value through manufacturing reliability, dose flexibility, and specialty packaging than through a novel composition alone.
FAQs
Can dichlorphenamide be formulated as a 25 mg tablet?
Yes. A 25 mg tablet is a logical lifecycle product for titration and patients who cannot accurately split a 50 mg tablet. It would require appropriate CMC, dissolution, content-uniformity, stability, and bioequivalence support.
Is lactose a suitable excipient for dichlorphenamide?
Lactose is used in the approved Keveyis tablet and is suitable as a conventional diluent, subject to compatibility and stability testing. A lactose-free formulation could be developed but would not automatically provide regulatory or commercial advantages.
Does dichlorphenamide have biosimilar competition?
No. Dichlorphenamide is a chemically synthesized small molecule. Competition would proceed through generic-drug pathways, not biosimilar pathways.
What is the best dosage form for pediatric dichlorphenamide use?
A liquid or dispersible dosage form would provide the greatest dosing flexibility. The formulation must address stability, uniformity, preservative control, taste, container compatibility, and accurate dose measurement.
Can a different excipient formulation avoid all dichlorphenamide patent risk?
No. A different excipient system may reduce exposure to composition claims, but method-of-use, dosage-regimen, manufacturing, or other patent claims may remain relevant. Current Orange Book listings and broader freedom-to-operate analysis control the launch assessment.
References
-
U.S. Food and Drug Administration. (2015). Keveyis (dichlorphenamide) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
